Page last updated: 2024-11-05

ici 204,219 and Lupus Erythematosus, Systemic

ici 204,219 has been researched along with Lupus Erythematosus, Systemic in 2 studies

zafirlukast: a leukotriene D4 receptor antagonist

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rosenwasser, LJ1
Finkel, TH1
Hunter, DJ1
Paisley, JE1
Finkel, RS1
Larsen, GL1

Other Studies

2 other studies available for ici 204,219 and Lupus Erythematosus, Systemic

ArticleYear
Leukotriene modifiers: new drugs, old and new reactions.
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Acetates; Anti-Asthmatic Agents; Asthma; Autoimmune Diseases; Chromones; Churg-Strauss Syndrome; Cyc

1999
Drug-induced lupus in a child after treatment with zafirlukast (Accolate).
    The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:3 Pt 1

    Topics: Anti-Asthmatic Agents; Asthma; Child; Female; Humans; Indoles; Leukotriene Antagonists; Lupus Erythe

1999